Home >
NEWS
Molnupiravir FDA Approval Status
Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog in development for the treatment of COVID-19.1.Molnupiravir works as an antiviral agent by inhibiting the replication of the SARS-CoV-2 virus, th..
2021-10-25
2020's party
We were having a league construction activity for celebrating that our company has got to a new point. We chose a hot spring hotel, since we were supposed to stay in GuangZhou Province because of COVID-19. We want to show you that our company is such a lovely ..
2021-02-03
The review of Senova at the CPhI exhibition in Shanghai in 2020
We firstly want to send the greatest congratulations for the successful and promising outcomes from CPhl exhibition 2020. We want to say thank you to everyone here, for your effort and confidence you’ve shown on us, given 2020 is already a tough year fo..
2020-12-29
SENOVA INVITATION LETTER FOR CPhI CHINA 2020
This is an invitation letter for anyone interested in CPhI China.CPhI China 2020 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. CPhI China is your ONE-STOP SHOP pharmaceutical platform in Asia.We hereby sin..
2020-12-04
Copyright Copyright (C) 2015-2035 Senova Technology Co. Ltd.
Address: 510# in Building 8 of North Area, Dayuan Industry Park, Xili, Nanshan District of Shenzhen,China 518055 Tel: +86-0755-8670 3119 QQ: 530953397 Email: info@senovatech.com
Address: 510# in Building 8 of North Area, Dayuan Industry Park, Xili, Nanshan District of Shenzhen,China 518055 Tel: +86-0755-8670 3119 QQ: 530953397 Email: info@senovatech.com